Positions

Selected Publications

Academic Article

Year Title Altmetric
2023 Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.  Cancer Discovery.  13:654-671. 2023
2022 Truly Man's Best Friend: Canine Cancers Drive Drug Repurposing in Osteosarcoma.  Clinical Cancer Research.  28:571-572. 2022
2022 Immune checkpoint inhibitor resistance in soft tissue sarcoma 2022
2021 Erratum: Correction: Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST (Oncotarget (2018) 9 33 (23018-23028)).  Oncotarget.  12:2435-2436. 2021
2021 A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma..  Journal of Clinical Oncology.  39:tps11583-tps11583. 2021
2021 Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma..  Journal of Clinical Oncology.  39:11508-11508. 2021
2020 A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.  European Journal of Cancer.  137:1-9. 2020
2020 Secondary Sarcomas: Biology, Presentation, and Clinical Care..  American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting.  40:1-12. 2020
2018 Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST.  Oncotarget.  9:23018-23028. 2018

Education And Training

  • Doctor of Medicine, Rush University 2015

    • Full Name

  • Vanessa Eulo